// App-Quantinova.ai

: Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMOTM Clinical Trial in iNHL

Researchers

Presenter

  • Pier Luigi Zinzani

Principal Investigators

  • Ian W. Flinn

  • Carole B. Miller

  • Scott A. Tetreault

  • Kirit M. Ardeshna

  • NgocDiep Le

  • Jonathan A. Pachter

  • Kam Sprott

  • Stephanie Lustgarten

  • David T. Weaver

  • Nina D. Wagner-Johnston

Medical Centers

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • Sarah Cannon Research Institute/Tennessee Oncology, Brentwood, TN

  • St. Agnes Cancer Institute, Baltimore, MD

  • Florida Cancer Specialists and Research Institute, Sarasota, FL

  • Haematology, University College London Hospitals NHS Foundation Trust (UCLH), London, United Kingdom

  • Verastem Oncology, Needham, MA

  • Siteman Cancer Center, Washington University, Saint Louis, MO

Locations

  • Italy

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Autoimmune (AI)

Disease

  • Neutropenia

  • Pulmonary alveolar proteinosis

  • Ulcerative colitis

Biomarkers

  • N/A

Drug/Treatment

  • Duvelisib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01882803

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved